In this issue:
Intensive treatment regimens compared in early RA
Repeated rituximab treatment improves RA disease activity
Relative risks of CV events in AS and RA
Educating patients encourages gout medication adherence
Newly diagnosed gout: an increased mortality risk
Neutrophil decreases during TCZ: no increased infection risk
Allopurinol lowers risk of ventricular arrhythmias in gout
CV safety of celecoxib, naproxen, or ibuprofen
Immunosuppressants and cancer risks in SLE
Please login below to download this issue (PDF)